BLAVIAL
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Drug data last refreshed 56m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HUMIRA (adalimumab) is a fully human monoclonal antibody that inhibits tumor necrosis factor (TNF-α), a key inflammatory cytokine. It is approved for multiple autoimmune and inflammatory indications including rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. The drug works by binding to TNF-α and preventing its interaction with cell surface receptors, thereby suppressing inflammation.
$0.258BPart D
LOE ApproachingDeclining
As HUMIRA approaches loss of exclusivity, the brand team faces significant headcount contraction and transition to defensive strategies focused on patient retention and managed care contracting.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial
Started Sep 2026
160 enrolled
Juvenile Idiopathic Arthritis Associated UveitisUveitis, Anterior
A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis
Started Jul 2026
30 enrolled
Adult Non-infectious Uveitis
A Clinical Trail of Adalimumab in Treating Chinese Children With Severe Plaque Psoriasis
Started May 2026
30 enrolled
Severe Plaque Psoriasis in Chinese Children
Post - Marketing Case Registration Study on the Safety and Efficacy of Adalimumab Solution for Injection in Chinese Pediatric Patients With Moderate - to - Severe Active Crohn's Disease
Started May 2026
30 enrolled
Children Aged 6 Years and Above With Moderate - to - Severe Active Crohn's Disease
A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects
Started Mar 2025
444 enrolled
Healthy Adult Male
Worked on HUMIRA at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.